Author

S. Hingtgen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

A. B. Satterlee· 2 shared A. Baldwin· 1 shared A. Buckley· 1 shared A. Shelton· 1 shared A. Valdivia· 1 shared B. E. Mann· 1 shared C. Vaziri· 1 shared C. Wang· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. B. Satterlee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

X. Zhang, H. Taylor, A. Valdivia, R. Dasari, A. Buckley, E. Bonacquisti, J. Nguyen, K. Kanchi, D. L. Corcoran, L. E. Herring, D. A. Steindler, A. Baldwin, S. Hingtgen, A. B. Satterlee

The paper demonstrates that TRAIL-loaded exosomes from induced neural stem cells effectively target and kill brain cancer cells in vitro and in vivo.

bioRxiv · May 24, 2024Cancer Biology

Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma

X. Cheng, J. An, J. Lou, Q. Gu, W. Ding, G. Droby, Y. Wang, C. Wang, Y. Gao, A. Shelton, A. B. Satterlee, B. E. Mann, Y.-C. Hsiao, C.-W. Liu, K. Liu, , Y. Yang

This study identifies RAD18's role in TMZ resistance and hypermutation in GBM by linking it to TLS and MMR pathways through CRISPR screening and mutation analysis.

bioRxiv · Oct 16, 2023 · PreprintCancer Biology